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Objectives This study sought to examine the 3-year clinical outcomes in patients treated with the
Endeavor (Medtronic, Santa Rosa, California) zotarolimus-eluting stent (ZES) or the Cypher (Cordis,
Johnson & Johnson, Warren, New Jersey) sirolimus-eluting stent (SES) in routine clinical practice.
Background The long-term clinical outcome in patients treated with ZES in comparison with SES is unclear.
Methods The authors randomized 2,332 patients to ZES (n  1,162) or SES (n  1,170) implanta-
tion. Endpoints included major adverse cardiac events (MACE), a composite of cardiac death, myo-
cardial infarction, or target vessel revascularization; the individual endpoints of MACE; and deﬁnite
stent thrombosis.
Results At 3-year follow-up, the MACE rate was higher in patients treated with ZES than in patients
treated with SES (148 [12.9%] vs. 116 [10.1%]; hazard ratio [HR]: 1.33, 95% conﬁdence interval [CI]:
1.04 to 1.69; p  0.022). Target vessel revascularization was more frequent in the ZES group com-
pared with the SES group (103 [9.1%] vs. 76 [6.7%]; HR: 1.40, 95% CI: 1.04 to 1.89; p  0.025),
whereas the occurrence of myocardial infarction (3.8% vs. 3.3%) and cardiac death (2.8% vs. 2.8%)
did not differ signiﬁcantly. Although the rate of deﬁnite stent thrombosis was similar at 3-year fol-
low-up (1.1% vs. 1.4%), very late (12 to 36 months) deﬁnite stent thrombosis occurred in 0 (0%) pa-
tients in the ZES group versus 12 (1.1%) patients in the SES group (p  0.0005).
Conclusions Although the 3-year MACE rate is higher in patients treated with ZES versus SES, our
data highlight a late safety problem concerning deﬁnite stent thrombosis with the use of SES. This
ﬁnding underscores the importance of long-term follow-up in head-to-head comparisons of drug-
eluting stents. (Randomized Clinical Comparison of the Endeavor and the Cypher Coronary Stents in
Non-selected Angina Pectoris Patients [SORT OUT III]; NCT00660478) (J Am Coll Cardiol Intv 2012;5:
812–8) © 2012 by the American College of Cardiology Foundation
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813The 2 first-generation drug-eluting stents (DES), the
Cypher Select (Cordis, Johnson & Johnson, Warren, New
Jersey) sirolimus-eluting stent (SES) and the Taxus (Boston
Scientific, Natick, Massachusetts) paclitaxel-eluting stent
(PES), more than halved the need for new revascularizations
after coronary artery stent implantation (1–3). However, both
types of DES have been associated with increased risk of very
late (occurring later than 12 months following the index
procedure) stent thrombosis (ST) (4). The second-generation
zotarolimus-eluting Endeavor stent (ZES) has been associated
with an increased risk of ST within the first year after
implantation as compared with SES and PES (5–7). There
are, however, data indicating that ZES may be associated with
fewer target lesion revascularizations (TLR) beyond the first
year, but this issue has hitherto not been adequately addressed
in a larger randomized study with long-term follow-up (8).
he present study provides 3-year clinical outcomes in 2,332
outine clinical care patients with coronary artery disease
andomized to treatment with ZES versus SES.
ethods
Patients and study design. The SORT OUT (Danish Or-
anization for Clinical Trials with Clinical Outcome) III
rotocol has been previously described (5). Briefly, SORT
UT III is a multicenter, open-label, randomized, superiority
rial that enrolled patients from January 2006 through August
007 at 5 Danish high-volume PCI centers (5). Patients aged
8 years or older with an indication for DES implantation were
ligible. The only exclusion criteria were inability to provide
nformed consent; life expectancy1 year; allergy to acetylsal-
cylic acid, clopidogrel, ticlopidine, sirolimus, or zotarolimus; or
articipation in another randomized trial.
Patients with coronary artery disease were randomly
ssigned 1:1 to have either ZES (Endeavor Sprint,
edtronic, Santa Rosa, California) or SES (Cypher Se-
ect) implanted. The recommendation for dual antiplate-
et therapy included lifelong acetylsalicylic acid (75 mg
aily) and clopidogrel 75 mg daily for 1 year, in accordance
ith Danish guidelines.
The study complied with the Declaration of Helsinki and was
pproved by the local ethics committee. All patients provided
ritten, informed consent before participating in the trial.
Outcome measures and data management. Follow-up was
pre-specified to take place after 9 months, 18 months, 3
years, and 5 years. We assessed major adverse cardiac events
Copenhagen University Hospital, Copenhagen, Denmark; §Department of Cardiol-
ogy, Gentofte University Hospital, Gentofte, Denmark; and the Department of
Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.¶Department
of Cardiology, Odense University Hospital, Odense, Denmark; The study was
supported by unrestricted research grants from Cordis and Medtronic. Both compa-
nies had no influence on the study design, data collection, data analysis, data
interpretation; they did not have access to the clinical trial database, and they did not M(MACE), defined as the composite of cardiac death, myo-
cardial infarction (MI), and target vessel revascularization
(TVR). Other endpoints were all-cause death, cardiac
death, MI, TVR, TLR (stent  5-mm distal and proximal
edges), symptom-driven observation of restenosis (stent 
5-mm distal and proximal edges), and angiographically
verified (definite) ST. Independent study monitors blinded
to treatment assignment reviewed all repeat coronary angio-
grams and coronary interventions (balloon angioplasty, stent
implantation, and coronary artery bypass grafting). Symptom-
driven restenosis and definite ST were classified based on
review of angiograms and patient files. Landmark analyses
were performed for all endpoints by dividing the entire
follow-up period into the initial 12 months and the subse-
quent 24 months.
Clinical event detection. We used clinically driven event
detection to avoid study-induced reinterventions (5,9). Data on
mortality (cardiac and noncar-
diac), hospital admissions, coro-
nary angiography, repeat percuta-
neous coronary intervention (PCI),
and coronary bypass surgery were
obtained for all randomized pa-
tients from national Danish ad-
ministrative and health registries
(the Danish Civil Registration
system, the National Registry of
Causes of Death, the National
Registry of Patients, and the Dan-
ish Heart Registries). We defined
new MIs as rehospitalization for
MI after discharge following the
index PCI. We used the original
death certificates obtained from
the National Registry of Causes of
Deaths, combined with hospital
records, and data from the pa-
tient’s general practitioner to classify deaths according to the
underlying cause.
An independent endpoint committee blinded to treat-
ment assignment reviewed all events and classified all MIs
and deaths.
Statistical analysis. Distributions of continuous variables in
the ZES and SES groups were compared using either the
2-sample t test (or Cochran t test in the case of unequal
ariance) or the Mann-Whitney U test, depending on
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and Acronyms
DES  drug-eluting stent(s)
HR  hazard ratio
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
TLR  target lesion
revascularization
TVR  target vessel
revascularization
ZES  zotarolimus-eluting
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814whether the data followed a normal distribution. We
compared distributions of categorical variables using the
chi-square test.
We counted endpoint events occurring during the
follow-up period and compared rates for the 2 groups of
patients. Follow-up began on the date of the index PCI
procedure. In analyses of each outcome, follow-up contin-
ued until the date of an endpoint event, death, emigration,
or until 36 months after implantation, whichever occurred
first. Cumulative incidence curves were constructed based
on the cumulative incidence of endpoint events, taking into
account the competing risk of death. Further, landmark
analyses were performed as previously noted. Differences
between groups were estimated using the Cox proportional
hazards model. Patients treated with SES were used as the
reference in the analyses. All analyses were performed
according to intention-to-treat principles. We computed
the hazard ratio (HR) of MACE at 36-month follow-up for
relevant patient subgroups. A value of p  0.05 was
onsidered as significant. We used SAS software version 9.2
SAS Institute, Cary, North Carolina) for all analyses.
esults
We randomized 2,332 patients with 3,230 lesions to treat-
ment with ZES (1,162 patients, 1,619 lesions) or SES
(1,170 patients, 1,611 lesions). Of the 1,162 patients ran-
domized to ZES and the 1,170 patients randomized to
SES, 0 in the ZES group and 6 in the SES group had
incomplete follow-up due to emigration and were censored
on the day of emigration (Fig. 1). Complete data were
available for 2,223 patients (99.6%).
Table 1 summarizes the baseline patient characteristics.
The 3-year clinical outcomes and the landmark analysis of
events occurring after year 1 are presented in Table 2 and
Figure 1. Flow Diagram of the SORT OUT III Trial
CI  conﬁdence interval; HR  hazard ratio; MACE  major adverse cardiac e
Cypher Coronary Stents in Non-selected Angina Pectoris Patients.illustrated for MACE, TLR, and definite ST in Figures 2,3, and 4, respectively. The 3-year MACE rate was signifi-
cantly higher in patients receiving ZES than SES. The
landmark analysis showed that this difference primarily
occurred during the first year, whereas no significant differ-
ence was observed for the following 2 years.
The superiority of SES with regard to MACE was due
primarily to a significant disparity in TLR, and subsequently
TVR, between the ZES and SES groups. The landmark
analyses of TLR showed that patients receiving ZES had
approximately a 4-fold higher risk of TLR during year 1, with
an almost flat time-to-event curve after year 2 (Fig. 3). By
contrast, the TLR rate for patients receiving SES seemed to
increase steadily throughout the 3 years of follow-up.
The timing of definite ST events is illustrated in Figure 4.
At 1 year, definite ST had occurred more frequently in the
ZES group compared with the SES group, whereas there
SORT OUT III  Randomized Clinical Comparison of the Endeavor and the
Table 1. Baseline Characteristics of Patients Receiving ZES and SES at
3-Year Follow-Up in the SORT OUT III Trial
ZES
(n  1,162)
SES
(n  1,170)
Age, yrs 64.310.7 64.310.8
Men 852 (73) 862 (74)
Current smoker 347 (32) 341 (32)
Diabetes mellitus 161 (15) 175 (14)
Hypertension 605 (54) 569 (51)
Hypercholesterolemia 781 (70) 757 (68)
History of myocardial infarction 285 (26) 302 (27)
Previous percutaneous coronary intervention 233 (21) 195 (17)
Previous coronary artery bypass operation 79 (7) 73 (7)
Acute coronary syndrome 506 (44) 546 (47)
Multivessel coronary artery disease 350 (31) 345 (30)
Values are mean SD or n (%).
SES  sirolimus-eluting stent(s); SORT OUT III  Randomized Clinical Comparison of the
Endeavor and the Cypher Coronary Stents in Non-selected Angina Pectoris Patients; ZES vents;zotarolimus-eluting stent(s).
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815were no very late ST events (0%) in the ZES group as
opposed to 12 events (1.1%) in the SES group (risk
difference  1.1%, 95% confidence interval [CI]: 1.7%
to 0.4%; p  0.0005) between 1 and 3 years. For very late
T, the number needed to harm was 91 with use of SES in
omparison with ZES. Overall, however, there were no
tatistically significant difference in the number of STs at
-year follow-up. Definite ST caused 14 (64%) of the 22
Is observed within year 1, and 12 (23%) of the 53 MIs
hat occurred between 1 and 3 years of follow-up. Resteno-
is was observed more frequently in the SES group after 1
ear.
As illustrated in Figure 5, findings concerning MACE
emained consistent across subgroups categorized by age,
ex, diabetes, acute coronary syndromes, lesions in left
nterior descending artery, and complex lesions at 3-year
ollow-up.
iscussion
The SORT OUT III trial is an open-label multicenter
randomized superiority trial, which compares clinical out-
comes after ZES versus SES implantation in a PCI popu-
lation receiving routine clinical care. The previously pub-
lished 9- and 18-month results showed that ZES was
inferior to the SES with regard to both safety and efficacy
endpoints (5). Specifically, SES was associated with lower
rates of ST at 9 months, lower rates of MI at both 9 and 18
Table 2. Three-Year Clinical Outcomes of Patients Re
ZES (n  1,162)
0–36 months
Combined endpoint (MACE)* 148 (12.9)
Death 85 (7.3)
Cardiac death 32 (2.8)
Myocardial infarction 43 (3.8)
Deﬁnite stent thrombosis 13 (1.1)
Target vessel revascularization 103 (9.1)
Target lesion revascularization 77 (6.8)
Clinical in-stent restenosis† 66 (5.8)
12–36 months
Combined endpoint (MACE)* 55 (5.3)
Death 54 (4.8)
Cardiac death 18 (1.6)
Myocardial infarction 22 (2.0)
Deﬁnite stent thrombosis 0 (0)
Target vessel revascularization 25 (2.4)
Target lesion revascularization 15 (1.4)
Clinical in-stent restenosis† 15 (1.4)
Values are n (%). *The composite of cardiac death, myocardial infarc
pre-planned follow-up angiography. Clinical in-stent restenosis is the
pectoris or acute coronary syndromes. ‡Fisher’s exact test.
CI confidence intervals; MACEmajor adverse cardiac event(smonths, and a lower rate of all-cause mortality at 18months. The current 3-year follow-up showed that SES
remained superior to ZES with regard to MACE, TVR,
and TLR. This superiority was driven primarily by a
reduced risk of TLR. After 3 years, the safety-related
endpoints (ST, MI, and mortality) no longer differed
between the ZES and SES groups. As a novel observation,
however, we found that SES implantation was associated
with a significantly increased risk of very late ST as
compared with ZES implantation. Moreover, the HR of
2.19 (5.2% absolute MACE difference) at 18-month
follow-up in favor of SES was reduced to 1.33 (2.8%
absolute MACE difference) at 3-year follow-up. Combined,
these results indicate that the inferiority of the ZES, as
compared with the SES, decreases over time. This finding is
in accordance with the 5-year results of the ENDEAVOR III
study (A Randomized Controlled Trial of the Medtronic
Endeavor Drug [ABT-578] Eluting Coronary Stent System
Versus the Cypher Sirolimus-Eluting Coronary Stent Sys-
tem in De Novo Native Coronary Artery Lesions), in which
the progression of MACE was significantly more common
in patients receiving SES than those receiving ZES (10).
Therefore, our results highlight the importance of long-
term follow-up in randomized studies evaluating new DES.
We found that SES implantation was associated with a
higher risk of very late ST, occurring at a rate of approxi-
mately 0.5% per year in the SES group compared with no
very late ST events in the ZES group. ZES and SES use
g the ZES and the SES in the SORT OUT III Trial
S (n  1,170) Hazard Ratio (95% CI) p Value
116 (10.1) 1.33 (1.04–1.69) 0.0223
69 (5.9) 1.25 (0.91–1.72) 0.17
32 (2.8) 1.02 (0.62–1.66) 0.95
37 (3.3) 1.19 (0.77–1.85) 0.44
16 (1.4) 0.83 (0.40–1.72) 0.61
76 (6.7) 1.40 (1.04–1.89) 0.0247
44 (3.9) 1.82 (1.25–2.63) 0.0016
33 (2.9) 2.08 (1.37–3.15) 0.0006
70 (6.4) 0.84 (0.59–1.19) 0.32
45 (3.9) 1.22 (0.82–1.82) 0.32
21 (1.9) 0.88 (0.47–1.64) 0.68
31 (2.8) 0.73 (0.42–1.26) 0.26
12 (1.1) — 0.0005‡
43 (3.9) 0.62 (0.38–1.01) 0.0551
28 (2.5) 0.57 (0.30–1.06) 0.0775
23 (2.1) 0.69 (0.36–1.32) 0.26
d clinically driven target vessel revascularization. †The study had no
on of in-stent restenosis by repeat angiography due to stable angina
abbreviations as in Table 1.ceivin
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816and differ with regard to drug release kinetics. These factors
potentially explain the observed differences between these 2
types of DES. ZES elutes zotarolimus through use of a
phosphorylcholine polymer. This phosphorylcholine poly-
mer is considered a noninflammatory alternative to other
polymers but has a faster drug elution rate (within 14 days)
than other DES. In comparison with SES, the ZES was
experimentally associated with a higher degree of inflam-
mation in the treated vascular wall at 30 days but also less
inflammation at 6 months (11). In accordance with these
experimental results, human pathology studies have shown
that SES is associated with localized strut hypersensitivity at
late follow-up (12,13). Further, evaluation of ZES and SES
using intravascular ultrasound showed that ZES induced
more uniform and complete neointimal coverage of the
stent struts at 8-month follow-up (14,15). This ZES-
associated lack of late-acquired incomplete stent apposition
Figure 2. MACE in the SORT OUT III Trial
Event rates of MACE, the primary endpoint, a composite of cardiac death,
myocardial infarction, and target vessel revascularization in the zotaroli-
mus-eluting (dotted line) versus sirolimus-eluting (straight line) stent
groups. (A) Event rates during the 3-year follow-up. (B) A landmark analysis
of events occurring after year 1. Abbreviations as in Figure 1.is believed to protect against very late ST. Our clinical dataextend these experimental, pathological, and intravascular
ultrasound findings by confirming a reduced risk of very late
ST associated with ZES use. The higher risk of ST
observed in the ZES group at short-term follow-up in our
and other studies (6,7) may be related to an overly rapid
elution of zotarolimus, whereas the higher rate of very late
ST observed in the SES group may represent the, probably,
polymer-related, localized strut hypersensitivity.
It should also be noted that the risk of ST was higher in
our “all-comer” trial than in patients with a relatively low
anatomic and clinical risk of adverse events. For example, in
the ENDEAVOR III study 1% of patients experienced
ST at 5-year follow-up, with no difference between ZES
and SES (10). Moreover, the problem with very late ST
seems unlikely to be confined to SES, as this outcome also
has been reported for other newer-generation DES. In the
BASKET-PROVE (Basel Stent Kosten-Effektivitäts Tri-
al–Prospektive Validation Examination), there were 2
(0.3%) (definite and probable) very late ST events in both
Figure 3. TLR in the SORT OUT III Trial
Event rates of target lesion revascularization (TLR) in the zotarolimus-eluting
(dotted line) versus sirolimus-eluting (straight line) stent groups. (A) Event
rates during the 3-year follow-up. (B) A landmark analysis of events occurring
after year 1. Abbreviations as in Figure 1.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 8 , 2 0 1 2 Maeng et al.
A U G U S T 2 0 1 2 : 8 1 2 – 8 The SORT OUT III 3-Year Follow-Up
817the SES and the everolimus-eluting stent groups between
12 and 24 months’ follow-up (16). At 2-year follow-up in
the RESOLUTE All-Comers trial, which compared the Res-
olute ZES versus an everolimus-eluting DES, 2 (0.2%) and 3
(0.3%) definite very late ST events were reported for the 2 DES
types, respectively (17). However, a noninferiority trial comparing
SES with a biolimus-eluting stent using a biodegradable polymer
in “all-comer” patients found a reduced risk of definite ST in
patients treated with the biodegradable polymer stent due to a
5-fold reduced risk of very late ST (18). Thus, it seems that
long-term follow-up, far beyond the traditional 1-year primary
endpoint, in large-scale clinical trials including all-comer patients
are needed to predict the long-term outcome, especially with
regard to ST.
TLR reduction was the main reason for the inferiority of
Figure 4. Definite ST in the SORT OUT III Trial
Event rates of deﬁnite stent thrombosis (ST) in the zotarolimus-eluting (ZES) (dot-
ted line) versus sirolimus-eluting (SES) (straight line) stent groups. (A) Event rates
during the 3-year follow-up. (B) A landmark analysis of events occurring after year
1. The ZES was associated with a higher rate of stent thrombosis at 1-year follow-
up, whereas very late stent thrombosis events did not occur. By contrast, the SES
had a steadily growing event rate of very late stent thrombosis, averaging approxi-
mately 0.5% per year. RD  risk difference; other abbreviations as in Figure 1.ZES compared with SES. The absolute TLR reduction was4.0% at 1-year follow-up and 2.9% at 3-year follow-up.
From a clinical point of view, TLR is caused either by ST or
in-stent restenosis. Angiographic data have indicated a
potential development of in-stent restenosis between 6 and
24 months with use of SES (8). However, the primary
explanation for the reduced difference between ZES and
SES at 3-year follow-up in our study was the increased risk
of very late stent restenosis in the SES group, whereas
symptom-driven detection of in-stent restenosis differed
only numerically, but not significantly, between the 2 groups
beyond 12 months.
Study limitations. It is a limitation of this study that data
regarding duration of dual antiplatelet therapy was not
collected. However, since November 2002, all patients
treated with coronary stent implantation in Denmark have
been recommended to receive 12 months dual antiplatelet
therapy, and all our patients in this study received reim-
bursement of costs related to clopidogrel treatment for 12
months. We therefore find it unlikely that the duration of
dual antiplatelet therapy differed between the groups.
Conclusions
The SES remained superior to ZES with regard to MACE,
TVR, and TLR at 36-month follow-up. The SES, however,
was associated with an increased risk of very late ST. Our
results highlight the importance of long-term follow-up in
randomized studies evaluating new DES.
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